Online inquiry

IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ24MR)

This product GTTS-WQ24MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ24MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11828MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ12546MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ9484MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ3588MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ12940MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ10229MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ12492MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ4087MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 836
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW